-
1
-
-
70449394029
-
Pancreatic islet in flammation in type 2 diabetes: From α and β cell compensation to dysfunction
-
Ehses JA, Ellingsgaard H, Böni-Schnetzler M, Donath MY. Pancreatic islet in flammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch Physiol Biochem 2009;115:240-247
-
(2009)
Arch Physiol Biochem
, vol.115
, pp. 240-247
-
-
Ehses, J.A.1
Ellingsgaard, H.2
Böni-Schnetzler, M.3
Donath, M.Y.4
-
2
-
-
41149115561
-
Islet inflammation in type 2 diabetes: From metabolic stress to therapy
-
Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31(Suppl. 2):S161-S164
-
(2008)
Diabetes Care
, vol.31
, pp. S161-S164
-
-
Donath, M.Y.1
Schumann, D.M.2
Faulenbach, M.3
Ellingsgaard, H.4
Perren, A.5
Ehses, J.A.6
-
5
-
-
84894580064
-
Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes
-
Butcher MJ, Hallinger D, Garcia E, et al. Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes. Diabetologia 2014;57:491-501
-
(2014)
Diabetologia
, vol.57
, pp. 491-501
-
-
Butcher, M.J.1
Hallinger, D.2
Garcia, E.3
-
6
-
-
34247170807
-
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
-
Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526
-
(2007)
N Engl J Med
, vol.356
, pp. 1517-1526
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
-
7
-
-
42449137013
-
The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus
-
Donath MY, Mandrup-Poulsen T. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat Clin Pract Endocrinol Metab 2008;4:240-241
-
(2008)
Nat Clin Pract Endocrinol Metab
, vol.4
, pp. 240-241
-
-
Donath, M.Y.1
Mandrup-Poulsen, T.2
-
8
-
-
69549105888
-
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
-
Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-1668
-
(2009)
Diabetes Care
, vol.32
, pp. 1663-1668
-
-
Larsen, C.M.1
Faulenbach, M.2
Vaag, A.3
Ehses, J.A.4
Donath, M.Y.5
Mandrup-Poulsen, T.6
-
9
-
-
0030175880
-
Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes
-
Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996;9:379-383
-
(1996)
J Autoimmun
, vol.9
, pp. 379-383
-
-
Verge, C.F.1
Gianani, R.2
Kawasaki, E.3
-
10
-
-
0032534668
-
Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes
-
Naserke HE, Ziegler A-G, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 1998;161:6963-6969
-
(1998)
J Immunol
, vol.161
, pp. 6963-6969
-
-
Naserke, H.E.1
Ziegler, A.-G.2
Lampasona, V.3
Bonifacio, E.4
-
11
-
-
0031953634
-
Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes
-
Kawasaki E, Yu L, Rewers MJ, Hutton JC, Eisenbarth GS. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes 1998;47:733-742
-
(1998)
Diabetes
, vol.47
, pp. 733-742
-
-
Kawasaki, E.1
Yu, L.2
Rewers, M.J.3
Hutton, J.C.4
Eisenbarth, G.S.5
-
12
-
-
0003137572
-
Predicting IDDM: Use of humoral immune markers
-
Palmer JP. Predicting IDDM: use of humoral immune markers. Diabetes Rev 1993;1:104-115
-
(1993)
Diabetes Rev
, vol.1
, pp. 104-115
-
-
Palmer, J.P.1
-
13
-
-
0022570021
-
Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis
-
Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986;35:237-241
-
(1986)
Diabetes
, vol.35
, pp. 237-241
-
-
Groop, L.C.1
Bottazzo, G.F.2
Doniach, D.3
-
14
-
-
0028258126
-
Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
-
Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303
-
(1994)
Diabet Med
, vol.11
, pp. 299-303
-
-
Zimmet, P.Z.1
Tuomi, T.2
Mackay, I.R.3
-
15
-
-
0034799480
-
Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes
-
Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001;50:1008-1013
-
(2001)
Metabolism
, vol.50
, pp. 1008-1013
-
-
Juneja, R.1
Hirsch, I.B.2
Naik, R.G.3
Brooks-Worrell, B.M.4
Greenbaum, C.J.5
Palmer, J.P.6
-
16
-
-
0027229335
-
Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients
-
Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993;16:902-910
-
(1993)
Diabetes Care
, vol.16
, pp. 902-910
-
-
Gottsäter, A.1
Landin-Olsson, M.2
Fernlund, P.3
Lernmark, A.4
Sundkvist, G.5
-
17
-
-
39749160476
-
The islet autoantibody titres: Their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus
-
van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med 2008;25:117-125
-
(2008)
Diabet Med
, vol.25
, pp. 117-125
-
-
Van Deutekom, A.W.1
Heine, R.J.2
Simsek, S.3
-
18
-
-
17844393918
-
Islet autoantibodies in clinically diagnosed type 2 diabetes: Prevalence and relationship with metabolic control (UKPDS 70)
-
Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005;48:695-702
-
(2005)
Diabetologia
, vol.48
, pp. 695-702
-
-
Davis, T.M.1
Wright, A.D.2
Mehta, Z.M.3
-
19
-
-
0031560175
-
UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
-
Turner R, Stratton I, Horton V, et al.; UK Prospective Diabetes Study Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997;350:1288-1293
-
(1997)
Lancet
, vol.350
, pp. 1288-1293
-
-
Turner, R.1
Stratton, I.2
Horton, V.3
-
20
-
-
17844403542
-
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)
-
Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005;48:703-708
-
(2005)
Diabetologia
, vol.48
, pp. 703-708
-
-
Bottazzo, G.F.1
Bosi, E.2
Cull, C.A.3
-
21
-
-
33750594322
-
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: Results of a blinded controlled study
-
Seyfert-Margolis V, Gisler TD, Asare AL, et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes 2006;55:2588-2594
-
(2006)
Diabetes
, vol.55
, pp. 2588-2594
-
-
Seyfert-Margolis, V.1
Gisler, T.D.2
Asare, A.L.3
-
22
-
-
70350534475
-
Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes
-
Herold KC, Brooks-Worrell B, Palmer J, et al.; Type 1 Diabetes TrialNet Research Group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009;58:2588-2595
-
(2009)
Diabetes
, vol.58
, pp. 2588-2595
-
-
Herold, K.C.1
Brooks-Worrell, B.2
Palmer, J.3
-
23
-
-
0030589224
-
Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins
-
Brooks-Worrell BM, Starkebaum GA, Greenbaum C, Palmer JP. Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol 1996;157:5668-5674
-
(1996)
J Immunol
, vol.157
, pp. 5668-5674
-
-
Brooks-Worrell, B.M.1
Starkebaum, G.A.2
Greenbaum, C.3
Palmer, J.P.4
-
24
-
-
0035871763
-
Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes
-
Brooks-Worrell B, Gersuk VH, Greenbaum C, Palmer JPP. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J Immunol 2001;166:5265-5270
-
(2001)
J Immunol
, vol.166
, pp. 5265-5270
-
-
Brooks-Worrell, B.1
Gersuk, V.H.2
Greenbaum, C.3
Palmer, J.P.P.4
-
25
-
-
65049083839
-
Improved T cell assay for identification of type 1 diabetes patients
-
Brooks-Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of type 1 diabetes patients. J Immunol Methods 2009;344:79-83
-
(2009)
J Immunol Methods
, vol.344
, pp. 79-83
-
-
Brooks-Worrell, B.1
Warsen, A.2
Palmer, J.P.3
-
27
-
-
34547605312
-
T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes
-
Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe β-cell lesions in phenotypic type 2 diabetes. Diabetes 2007;56:2110-2115
-
(2007)
Diabetes
, vol.56
, pp. 2110-2115
-
-
Goel, A.1
Chiu, H.2
Felton, J.3
Palmer, J.P.4
Brooks-Worrell, B.5
-
28
-
-
79951689303
-
Identification of autoantibody-negative autoimmune type 2 diabetic patients
-
Brooks-Worrell BM, Reichow JL, Goel A, Ismail H, Palmer JP. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 2011;34:168-173
-
(2011)
Diabetes Care
, vol.34
, pp. 168-173
-
-
Brooks-Worrell, B.M.1
Reichow, J.L.2
Goel, A.3
Ismail, H.4
Palmer, J.P.5
-
29
-
-
84872166396
-
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients
-
Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013;171:164-170
-
(2013)
Clin Exp Immunol
, vol.171
, pp. 164-170
-
-
Brooks-Worrell, B.M.1
Palmer, J.P.2
-
30
-
-
0032940245
-
Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients
-
Brooks-Worrell BM, Juneja R, Minokadeh A, Greenbaum CJ, Palmer JP. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999;48:983-988
-
(1999)
Diabetes
, vol.48
, pp. 983-988
-
-
Brooks-Worrell, B.M.1
Juneja, R.2
Minokadeh, A.3
Greenbaum, C.J.4
Palmer, J.P.5
-
31
-
-
84855185039
-
Standards of medical care in diabetes - 2012
-
American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl. 1):S11-S63
-
(2012)
Diabetes Care
, vol.35
, pp. S11-S63
-
-
American Diabetes Association1
-
33
-
-
79952279727
-
Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: Efforts to harmonize procedures among the laboratories
-
Bingley PJ, Williams AJ, Colman PG, et al.; T1DGC. Measurement of islet cell antibodies in the Type 1 Diabetes Genetics Consortium: efforts to harmonize procedures among the laboratories. Clin Trials 2010;7(Suppl.):S56-S64
-
(2010)
Clin Trials
, vol.7
, pp. S56-S64
-
-
Bingley, P.J.1
Williams, A.J.2
Colman, P.G.3
-
34
-
-
56649115489
-
Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
-
Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
-
(2008)
Diabetes Care
, vol.31
, pp. 2188-2192
-
-
Sosenko, J.M.1
Palmer, J.P.2
Rafkin-Mervis, L.3
-
35
-
-
84899074071
-
CD8 T cell reactivity to islet antigens is unique to type 1 while CD4 T cell reactivity exists in both type 1 and type 2 diabetes
-
Sarikonda G, Pettus J, Phatak S, et al. CD8 T cell reactivity to islet antigens is unique to type 1 while CD4 T cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun 2014;50:77-82.
-
(2014)
J Autoimmun
, vol.50
, pp. 77-82
-
-
Sarikonda, G.1
Pettus, J.2
Phatak, S.3
-
36
-
-
33846126592
-
Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity
-
Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 88-92
-
-
Wang, J.1
Miao, D.2
Babu, S.3
-
37
-
-
36448978896
-
Type 1 diabetes as a relapsing-remitting disease?
-
von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988-994
-
(2007)
Nat Rev Immunol
, vol.7
, pp. 988-994
-
-
Von Herrath, M.1
Sanda, S.2
Herold, K.3
-
38
-
-
79959704370
-
HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion
-
Williams RC, Muller YL, Hanson RL, et al. HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion. Diabetologia 2011;54:1684-1692
-
(2011)
Diabetologia
, vol.54
, pp. 1684-1692
-
-
Williams, R.C.1
Muller, Y.L.2
Hanson, R.L.3
|